Tirzepatide (GLP-1/GIP Dual Agonist)
The active molecule in Mounjaro — Eli Lilly's dual GLP-1 and GIP receptor agonist that outperforms semaglutide with 21–22% average weight loss. Approved in India March 2025. The most potent approved metabolic drug in 2026.
Tirzepatide (Mounjaro) received CDSCO approval and launched in India in March 2025 at ₹13,125–₹25,781/month. Cumulative India sales reached ₹600 crore by December 2025 — the fastest uptake of any GLP-1 drug in India.
What Is Tirzepatide?
Tirzepatide is a synthetic peptide developed by Eli Lilly that simultaneously activates two incretin hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism makes it a fundamentally different class of drug from semaglutide, which activates only GLP-1 receptors.
Tirzepatide is the active molecule in Mounjaro (for type 2 diabetes) and Zepbound (for weight management, available in the US but not yet separately branded in India). In India, all tirzepatide is currently marketed as Mounjaro across both indications.
Dual Mechanism — GLP-1 + GIP
Understanding why tirzepatide outperforms semaglutide requires understanding what GIP does on top of GLP-1:
- GLP-1 receptor activation (shared with semaglutide): Suppresses appetite via hypothalamic receptors, slows gastric emptying, enhances glucose-dependent insulin secretion, suppresses glucagon
- GIP receptor activation (unique to tirzepatide): Sensitizes adipocytes (fat cells) to insulin, potentially reducing visceral fat accumulation; may amplify the appetite-suppressing effects of GLP-1 through synergistic central nervous system action; enhances beta-cell function and potentially beta-cell mass preservation
The GIP component was initially counterintuitive — early data suggested GIP agonism might promote fat storage. However, tirzepatide's real-world and clinical trial data showed the opposite: the GIP activation at pharmacological doses combined with GLP-1 activation appears to enhance fat mobilization and insulin sensitivity beyond what GLP-1 alone achieves. The SURMOUNT-1 trial (PubMed, 2022) confirmed this superiority.
SURMOUNT Trials — Evidence Summary
| Trial | Population | Duration | Weight Loss (15mg) | Key Finding |
|---|---|---|---|---|
| SURMOUNT-1 | Obesity, no T2D | 72 weeks | 22.5% | 57% achieved ≥20% weight loss |
| SURMOUNT-2 | T2D with obesity | 72 weeks | 15.7% | HbA1c reduced 2.1% at max dose |
| SURMOUNT-5 | Head-to-head vs semaglutide 2.4mg | 72 weeks | 20.2% vs 13.7% | Tirzepatide 47% more weight loss than Wegovy |
| SURPASS-CVOT | T2D high CV risk | Ongoing | — | Cardiovascular outcomes data expected |
In SURMOUNT-1, participants on tirzepatide 15mg were 3.2 times more likely to achieve ≥15% weight loss compared to those on semaglutide 2.4mg — the most compelling head-to-head comparison to date.
India Pricing Breakdown by Dose
| Dose (4 pens/month) | Approx. Price/Month (India) | Phase of Titration |
|---|---|---|
| 2.5mg/week | ₹13,125 | Weeks 1–4 (starting dose) |
| 5mg/week | ₹15,600 | Weeks 5–8 |
| 7.5mg/week | ₹17,800 | Weeks 9–12 |
| 10mg/week | ₹20,000 | Weeks 13–16 |
| 12.5mg/week | ₹23,000 | Weeks 17–20 |
| 15mg/week | ₹25,781 | Week 21+ (maximum dose) |
12-Week Titration Protocol
Tirzepatide is titrated every 4 weeks, slower than Ozempic but necessary for GI tolerability at higher doses:
- Weeks 1–4: 2.5mg once weekly
- Weeks 5–8: 5mg once weekly
- Weeks 9–12: 7.5mg once weekly
- Weeks 13–16: 10mg once weekly
- Weeks 17–20: 12.5mg once weekly
- Week 21+: 15mg once weekly (maximum dose)
Many patients achieve excellent results at 5–10mg without needing to reach the maximum dose. If side effects are significant, titration can be paused at the current dose for an additional 4 weeks.
Insulin Resistance Reversal
Tirzepatide's effects on insulin resistance are more pronounced than semaglutide. In the SURMOUNT-2 trial, participants with T2D achieved HbA1c reductions of 2.1% at max dose — comparable to the best diabetes medications available. More importantly, a significant proportion of T2D patients in trials achieved HbA1c below 5.7% (non-diabetic range), suggesting functional reversal of type 2 diabetes in some individuals.
This is driven by both weight loss (visceral fat reduction improves hepatic insulin sensitivity) and the direct insulin-sensitizing effects of GIP receptor activation on adipose tissue. Fasting insulin and HOMA-IR show dramatic improvement within 12 weeks at therapeutic doses.
Body Composition and Resistance Training
Tirzepatide causes even greater total weight loss than semaglutide — which means the lean mass loss risk is proportionally high if not addressed. Data from SURMOUNT trials showed the lean mass percentage of total weight lost was similar to semaglutide (~25–40% lean tissue). With greater absolute weight loss, the absolute lean mass loss can be significant without countermeasures.
Non-negotiable: Creatine 3–5g/day + resistance training 3x/week + protein 1.2–1.6g/kg/day. Consider DEXA or InBody scan at baseline and every 6 months to track lean vs fat mass changes separately from total weight.
Biomarker Connections
- HbA1c: Dramatic improvement in T2D patients — expect 1.5–2.1% reduction at max dose
- Fasting insulin / HOMA-IR: Often normalizes within 12–24 weeks on therapeutic doses
- Triglycerides: Significant reduction (often 30–40%) — one of the strongest triglyceride-lowering effects of any drug
- ApoB and LDL: Modest improvement (10–15% LDL reduction)
- ALT/AST: Substantial reduction in those with NAFLD/NASH — tirzepatide has shown liver fat reduction of >50% in some studies
- Uric acid: Often improves with weight loss — relevant for gout-prone Indian patients
Frequently Asked Questions
Is tirzepatide better than semaglutide for weight loss?
Yes, in head-to-head data tirzepatide consistently outperforms semaglutide. SURMOUNT-5 showed 47% more weight loss with tirzepatide (20.2%) versus semaglutide 2.4mg (13.7%). Participants were 3.2x more likely to achieve ≥15% weight loss. The dual GLP-1 + GIP mechanism explains this superiority.
How much does tirzepatide cost in India?
Mounjaro (tirzepatide) costs ₹13,125–₹25,781 per month in India depending on dose. The starting 2.5mg dose is cheapest; the full 15mg dose is most expensive. Generic tirzepatide is not yet available in India as of 2026 — expect generics from 2027 as patents expire.
How does tirzepatide work differently from Ozempic?
Ozempic only activates GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP receptors simultaneously. GIP activation adds fat cell insulin sensitization, potentially amplified appetite suppression via the CNS, and enhanced beta-cell function — producing greater weight loss and metabolic improvement than GLP-1 alone.
What labs should I test before starting tirzepatide?
Essential pre-treatment tests: HbA1c, fasting glucose, fasting insulin + HOMA-IR, full lipid panel with ApoB, TSH, amylase, lipase, ferritin, Vitamin B12, Vitamin D (25-OH), and a basic metabolic panel. If you have diabetes, get retinal screening. These establish baseline values to track treatment response at 3-month intervals.